Low-dose irradiation for reversing immunotherapy resistance: how to translate?

The use of low-dose irradiation (LDI) for mobilizing innate and adaptive immunity is gaining interest among the scientific community. Recent evidence suggests that LDI can reprogramme the tumor microenvironment, induce inflammation and turn cold tumors susceptible to immunecheckpoint blockade therapy. Translating immuno-radiation preclinical findings in the clinic is more challenging than expected. We propose therapeutic strategies for combining LDI with immunotherapy, and emphasize the importance of pursuing clinical research to determine optimal radiation dosage, fractionation, volumes, and sequencing to stimulate immune-mediated tumor responses.

Automated summary

The use of low-dose irradiation for mobilizing immunity is gaining interest. Recent evidence suggests its ability to reprogram the tumor microenvironment and enhance the effectiveness of immune checkpoint blockade therapy. Translating preclinical findings to the clinic is challenging, and further research is needed to determine optimal radiation dosage and sequencing for immune-mediated tumor responses.